Moderna shares fall 2.68% after Q2 2026 cash balance drops to $6.9 billion following $950 million settlement payment
AI مارکیٹ کا خلاصہ
Moderna's Q2'26 revenue beat expectations and 2026 sales guidance was reaffirmed, but investor focus shifted to liquidity and pipeline risk. Cash fell to $6.9B from $7.5B, largely due to a $950M litigation settlement payment, highlighting sizable cash outflows. Additionally, the norovirus vaccine missed interim success criteria, offsetting optimism ahead of the August 5 PDUFA decision for its flu candidate.
اثر کی سطح
● درمیانہ
متاثرہ اثاثے
NCSKMRNA2USD/USDT-2.50%
AI تجزیاتی سمجھ · NCSKMRNA2USD/USDTAI تجزیاتی سمجھ
▼ Bearish
ابھی ٹریڈ کریں
⚠️ AI سے تیار کردہ تجزیاتی سمجھ خبروں کے مواد پر مبنی ہے اور صرف معلوماتی مقاصد کے لیے فراہم کی گئی ہے۔ یہ سرمایہ کاری کا مشورہ نہیں ہے اور نہ ہی BingX کے خیالات کی نمائندگی کرتی ہے۔ سرمایہ کاری میں رسک شامل ہے۔ براہ کرم ذمہ داری سے ٹریڈ کریں۔
Moderna reported second-quarter 2026 revenue of $145 million, topping expectations. However, cash and cash equivalents fell to $6.9 billion from $7.5 billion at the end of March, mainly after a $950 million litigation settlement payment in July. R&D spending declined 7% year over year as several late-stage programs wound down. The company reaffirmed its full-year 2026 sales guidance and said it expects roughly 50% of revenue to come from international markets, but the stock fell Friday as investors focused on liquidity pressure from the large cash outflow.
